MPT | Ticker Profile - Titan Protect

MPT

Medical Properties Trust, Inc.

Real Estate · REIT - Healthcare Facilities · NYQ

$4.98

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$3.1B

Total market value of the company

Trailing P/E

N/A

Forward P/E

31.21

Based on estimated future earnings — lower means cheaper

Rev Growth

+12.6%

Year-over-year revenue change

Profit Margin

-11.5%

How much profit the company keeps from each dollar of revenue

ROE

-2.7%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$5.00

+0% from current price — median analyst estimate

Recommendation

HOLD

Consensus view from 7 analysts covering this stock

About Medical Properties Trust, Inc.

Medical Properties Trust, Inc. is a self-advised real estate investment trust to acquire and develop net-leased hospital facilities. From its inception in Birmingham, Alabama, the Company has grown to become one of the world's largest owners of hospital real estate with 388 facilities and approximately 39,000 licensed beds in nine countries and across three continents as of September 30, 2025. MPT's financing model facilitates acquisitions and recapitalizations and allows operators of hospitals to unlock the value of their real estate assets to fund facility improvements, technology upgrades and other investments in operations. Medical Properties Trust, Inc. was incorporated in 2003.

https://www.medicalpropertiestrust.com

Country: United States Employees: 121 Industry: REIT - Healthcare Facilities

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

0.420

Positive but modest risk-adjusted returns

Kelly Fraction

-0.0039

No positive edge detected — the data suggests staying out

Calmar Ratio

0.232

Drawdown risk outweighs the returns — higher risk profile

Annual Return

9.4%

Historical annualised return based on price data

Max Drawdown

-40.4%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.46

Moves slightly more than the broader market

52W High

$6.47

23% below the year high

52W Low

$3.95

26% above the year low

Avg Volume

5,792,054

Average daily shares traded — higher means easier to buy and sell

Short Ratio

23.9

Days it would take all short sellers to cover — higher means more crowded

Short % Float

29.7%

Very high short interest — potential squeeze candidate

Div Yield

699.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.21

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

212.56

Heavy leverage — higher financial risk if revenues decline

Current Ratio

1.18

Adequate but worth monitoring

Quick Ratio

1.03

Like current ratio but excludes inventory — stricter test

Gross Margin

96.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

58.2%

Profit from core operations before interest and tax

Free Cash Flow

$782M

Positive — the business generates more cash than it spends

Revenue (TTM)

$1.1B

Total revenue over the last 12 months

Net Income

$-127,180,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$8.00

Target Median

$5.00

Target Low

$5.00

Political Trading Activity

Congressional trading disclosures involving this instrument

Date	Politician	Party	Type	Amount
30 Apr2026	Dave McCormick	Republican	sell	100K–250K

Source: Congressional disclosure filings. View all political trades at

Insider Intelligence

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go